

effective June 13, 2000, (section 306(d)(3)(B)(i) of the act).

Dated: June 6, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 00-14806 Filed 6-12-00; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 00F-1332]

Ecolab, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ecolab, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a mixture of peroxyacetic acid, octanoic acid, acetic acid, hydrogen peroxide, peroxyoctanoic acid, and 1-hydroxyethylidene-1,1-diphosphonic acid as an antimicrobial agent on red meat carcasses.

DATES: Submit written comments on the petitioner's environmental assessment by July 13, 2000.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Robert L. Martin, Center for Food Safety and Applied Nutrition (HFS-215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204-0001, 202-418-3074.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 0A4720) has been filed by Ecolab, Inc., Ecolab Center, 370 Wabasha St., St. Paul, MN 55102. The petition proposes to amend the food additive regulations in 21 CFR part 173 (21 CFR part 173) to provide for the safe use of a mixture of peroxyacetic acid, octanoic acid, acetic acid, hydrogen peroxide, peroxyoctanoic acid, and 1-hydroxyethylidene-1,1-diphosphonic acid as an antimicrobial agent on red meat carcasses.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations issued under

the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may submit to the Dockets Management Branch written comments by July 13, 2000. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the *Federal Register* in accordance with 21 CFR 25.40(c).

Dated: May 30, 2000.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 00-14906 Filed 6-12-00; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Gastrointestinal Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Gastrointestinal Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on June 26 and 27, 2000, 8:30 a.m. to 5:30 p.m.

Location: Marriott Washington Center, Ballrooms A through E, 9751 Washington Blvd., Gaithersburg, MD.

Contact Person: Thomas H. Perez, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-6758, e-mail at PerezT@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12538. Please call the Information Line for up-to-date information on this meeting.

Agenda: On June 26, 2000, the committee will discuss new drug application (NDA) 21-200, Zelmac™ (tegaserod), Novartis Pharmaceuticals Corp., for the treatment of abdominal pain and discomfort, bloating and altered bowel function in patients with irritable bowel syndrome who have predominant symptoms of pain, discomfort, and constipation. On June 27, 2000, the committee will discuss risk management of post-marketing adverse events associated with NDA 21-107, Lotronex™ (alosetron) Glaxo Wellcome.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by June 19, 2000. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before June 19, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

FDA regrets that it was unable to publish this notice 15 days prior to the June 26 and 27, 2000, Gastrointestinal Drugs Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Gastrointestinal Drugs Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: June 5, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00-14805 Filed 6-12-00; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

White House Initiative on Asian Americans and Pacific Islanders President's Advisory Commission; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), announcement is made of the following National Advisory body scheduled to conduct a public meeting by videoconference during the month June 2000.

Name: President's Advisory Commission on Asian Americans and Pacific Islanders (AAPIs).

Date and Time: June 26, 2000; 4:00 p.m.—6:00 p.m. EST.

The meeting is open to the public.

The President's Advisory Commission on AAPIs will conduct a public meeting by videoconference on June 26, from 4:00 p.m. to 6:00 p.m. EST inclusive. The meeting is open to the public; however, teleconference lines are limited. Please call Mr. Tyson Nakashima at (301) 443-2492, if you are interested in participating in the call and to

obtain the dial-in number. Agenda items will include, but will not be limited to: Approval of May Commission Meeting minutes; reports from subcommittees; administrative tasks; deadlines; and the upcoming Town Hall and Commission meetings.

The purpose of the Commission is to advise the President on the issues facing Asian Americans and Pacific Islanders (AAPIs). The President's Advisory Commission on AAPIs will be seated through June 7, 2001.

Requests to address the Commission should be made in writing and should include the name, address, telephone number and business or professional affiliation of the interested party. Individuals or groups addressing similar issues are encouraged to combine comments and present through a single representative. The allocation of time for remarks may be adjusted to accommodate the level of expressed interest. Written requests should be faxed to (301) 443-0259. Anyone who has interest in joining any portion of the meeting or who requires additional information about the Commission should contact: Mr. Tyson Nakashima, Office of the White House Initiative on AAPIs, Parklawn Building, Room 10-42, 5600 Fishers Lane, Rockville, MD, 20857, Telephone (301) 443-2492. Anyone who requires special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mr. Nakashima no later than June 19, 2000.

Dated: June 6, 2000.

Jane M. Harrison,

Director, Division of Policy Review and Coordination.

[FR Doc. 00-14807 Filed 6-12-00; 8:45 am]

BILLING CODE 4160-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of Inspector General; Program Exclusions: May 2000

AGENCY: Office of Inspector General, HHS.

ACTION: Notice of program exclusions.

During the month of May 2000, the HHS Office of Inspector General imposed exclusions in the cases set forth below. When an exclusion is imposed, no program payment is made to anyone for any items or services (other than an emergency item or service not provided in a hospital emergency room) furnished, ordered or prescribed by an excluded party under the Medicare, Medicaid, and all Federal Health Care programs. In addition, no program payment is made to any business or facility, e.g., a hospital, that submits bills for payment for items or services provided by an excluded party. Program beneficiaries remain free to decide for themselves whether they will continue to use the services of an excluded party even though no program payments will be made for items and services provided by that excluded party. The exclusions have national effect and also apply to all Executive Branch procurement and non-procurement programs and activities.

Subject, city, state	Effective date
PROGRAM-RELATED CONVICTIONS	
AKIN, CHARLES PHILIP, RAFTWOOD, TX	06/20/00
AKOPYAN, GEVORK, LOS ANGELES, CA	06/20/00
AKOPYAN, DANIEL, SAN DIEGO, CA	06/20/00
BRIKER, RUSLAN, BROOKLYN, NY	06/20/00
BRITTAIN, RICHARD E JR, MANCHESTER, KY	06/20/00
CARABELLA, ROBERT, MANCHESTER, KY	06/20/00
CHARLES, JOSEPH N, BROOKLYN, NY	06/20/00
CHASSEREAU, DANIEL, EHRHARDT, SC	06/20/00
COLLIER, JORDYCE A, MEDFORD, OR	06/20/00
CORN, JOANN, DENVER, CO	02/14/99
CROW, DONNA M, SHENANDOAH, IA	06/20/00
DINE, THEODORE SR, N SYRACUSE, NY	06/20/00
DISHON, LORI A, BALTIMORE, MD	06/20/00
DOBY, KIMBERLY M, DENVER, CO	06/20/00
DOVALINA, ELSA, EAGLE PASS, TX	06/20/00
DURAND, DEVIN, ENCINITAS, CA	06/20/00
DURANONA, RAFAEL ECHAVARRIA, MIAMI, FL	06/20/00
EKIZYAN, OGANES, LOS ANGELES, CA	06/20/00
ELIZALDE, MARIA ROSA, MIAMI, FL	06/20/00
EMBRIANO, PETER J, SOMERS, CT	07/28/98
GARNER, WILMA J, BALTIMORE, MD	06/20/00
GODZHOYAN, ARPINE, LOS ANGELES, CA	06/20/00
GONZALEZ, WILFREDO, MIAMI, FL	06/20/00
GOODBODY, JOHN P, WEBSTER, NY	06/20/00
HERAVI, BIJAN, LOS ANGELES, CA	06/20/00
HERNDON, PATRICIA SUE, ENID, OK	06/20/00
ILYAS, ZAHID, EDISON, NJ	06/20/00
KIDS CHARIOT, INC, COLORADO SPRNGS, CO	06/20/00